2.2.0.25falsefalse006060 - Disclosure - License And Collaboration Agreementstruefalsefalse1falsefalseUSDfalsefalse4/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$c00035http://www.sec.gov/CIK0000038074duration2010-04-01T00:00:002010-12-31T00:00:00u000Standardhttp://www.xbrl.org/2003/iso4217USDiso42170u003Standardhttp://www.xbrl.org/2003/instancesharesxbrli0u001Standardhttp://www.xbrl.org/2003/instancepurexbrli0u002Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0frx_NotesToFinancialStatementsAbstractfrxfalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0frx_LicenseAndCollaborationAgreementsTextBlockfrxfalsenadurationDescription of material license agreements entered into in the current period, in which the entity is a participant and a...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.   License and Collaboration Agreements:</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2010, the Company entered into an agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of small molecule compounds discovered and developed by TransTech.  These glucokinase activator (GKA) compounds represent a novel class of glucose-lowering agents for the treatment of type II diabetes.  Under the terms of the agreement, the Company made an upfront payment of $50,000 to TransTech which was recorded to research and development expense.  The Company may also be obligated to pay TransTech up to $1,105,000 in upfront and milestone payments for the successful development and commercialization of these GKA compounds.  The Company will pay TransTech royalties on worldwide product sales and will be responsible for development and commercialization costs.  TransTech retains the rights in the Middle East and North Africa, while the Company received exclusive rights to the rest of the worldwide market.</font></div><div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div><div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the Company entered into two agreements with The Gruenenthal Group (Gruenenthal).  The first agreement was for the co-development and commercialization of GR 6005 and its follow-on compound GR 6006, small molecule analgesic compounds being developed by Gruenenthal for the treatment of moderate to severe chronic pain.  Under the terms of the agreement Forest made an upfront payment to Gruenenthal of $66,125, which was recorded to research and development expense, and may be obligated to pay additional development and commercialization milestones and royalties on net sales.  Pursuant to the agreement the Company will have exclusive rights in the United States and Canada with an option to co-promote in Europe.  Gruenenthal will have an option to co-promote in the United States and Canada.  Pursuant to the second agreement, the Company purchased all rights currently held by Gruenenthal for colistin and all rights previously licensed by the Company to Gruenenthal for Colobreathe.  Nebulized colistin is an antibiotic used in the treatment of cystic fibrosis, currently being marketed by Forest in the United Kingdom and Ireland.  Colobreathe is a novel dry powder inhaler containing colistin, developed by Forest and currently being reviewed by the European Medicines Agency.  Under the terms of the agreement, we were obligated to pay Gruenenthal $96,875 which was recorded to license agreements, product rights and other intangibles.</font></div>6.   License and Collaboration Agreements:In June 2010, the Company entered into an agreement with TransTech Pharma, Inc. (TransTech) for thefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescription of material license agreements entered into in the current period, in which the entity is a participant and a description of collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations under thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.No authoritative reference available.falsefalse12License And Collaboration AgreementsUnKnownUnKnownUnKnownUnKnownfalsetrue